Aspen Buy here, there and everywhere
What’s trending this week? Acquisitions it seems, with another major deal being announced by Aspen Pharmacare, who like us, have their roots in Durbz, the city where the sun never sets, where bunny chows just can’t be beat and where… oh, the deal, yes... the ninth-largest generic pharmaceutical manufacturer in the world has signed an agreement to acquire an active pharmaceutical ingredient (API) manufacturing business from Merck for R10biljoens. The manufacturing facility, based in the Netherlands, means that Aspen will now have a presence in the one continent where it was absent, viz. Europe, and places the pharmaceutical giant is a great position to continue reinforcing its global competitiveness. The plant will produce chemicals for niche products in categories such as hormones, steroids and anti-coagulants, very popular treatments in hospitals and globally apparently. All this on the back of a bid by Aspen to buy two of GSK’s branded thrombosis medicines, as well as a manufacturing facility for an undisclosed amount earlier in June.
Comment: The sky is the limit it seems for Aspen, and why not?